| Literature DB >> 32713198 |
Jiasian Teh1,2, Ellen O'Connor1,2, Jonathon O'Brien3, Wei Mou Lim1, Michael Taylor4, Alexander Heriot1, Robert Ramsay1,4, Nathan Lawrentschuk1,3,5.
Abstract
Penile squamous cell carcinoma (SCC) is a rare and aggressive urological malignancy. Advanced penile SCC requires multimodal management, including surgery and systemic therapy. Given its rarity, there have been few substantial advances in our understanding of the molecular and genomic drivers of penile SCC, especially for patients with relapsed or advanced disease. In this review, we discuss the molecular and genomic landscape of penile SCC, clinical trials in progress and implications for novel therapeutic targets. Future work should focus on preclinical models to provide a platform for investigation and validation of new molecular pathways for testing of therapeutics.Entities:
Keywords: immunotherapy; pathogenesis; penile cancer; solid tumor; squamous cell carcinoma
Mesh:
Substances:
Year: 2020 PMID: 32713198 DOI: 10.2217/fon-2020-0434
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404